Short answer
Boston Scientific (BSX) filed its Q1 2025 10-Q quarterly report on May 1, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $4.7B (up 20.9% year over year) with net income of $674M.
Q1 2025 key financials · XBRL
- Revenue
- $4.7B
- +20.9% YoY
- Net income
- $674M
- +36.2% YoY
- Operating margin
- 19.8%
- Gross margin
- 68.8%
- EPS (diluted)
- $0.45
- +36.4% YoY
Source: XBRL data from the Boston Scientific (BSX) Q1 2025 10-Q on SEC EDGAR. USD.
Boston Scientific Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New insider trading risk: EVP Joseph F. Fitzgerald terminated May 23, 2024 Rule 10b5-1 plan, started new plan on Feb 27, 2025 for 306,372 shares sales
- Most impactful legal risk: compliance with Rule 10b5-1(c) trading plans to avoid insider trading violations, including mandatory cooling-off periods
- Financial risk update: new 3.000% Senior Note due 2031 and 3.250% Senior Note due 2034 issued, indicating updated debt maturity profiles
- Operational risk: reliance on timely execution of pre-established stock sale plans based on price thresholds impacting executive stock liquidity
- No material changes reported in broader risk factors from prior 10-K filings beyond insider trading and debt updates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Boston Scientific quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.